KR101302841B1 - 장용코팅에 적합한 판크레아틴 미세펠릿 코어 - Google Patents

장용코팅에 적합한 판크레아틴 미세펠릿 코어 Download PDF

Info

Publication number
KR101302841B1
KR101302841B1 KR1020087006201A KR20087006201A KR101302841B1 KR 101302841 B1 KR101302841 B1 KR 101302841B1 KR 1020087006201 A KR1020087006201 A KR 1020087006201A KR 20087006201 A KR20087006201 A KR 20087006201A KR 101302841 B1 KR101302841 B1 KR 101302841B1
Authority
KR
South Korea
Prior art keywords
pancreatin
pancreatin micropellet
core
weight
cellulose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1020087006201A
Other languages
English (en)
Korean (ko)
Other versions
KR20080034516A (ko
Inventor
게오르게 쉬리에오우트
클라우스-주르겐 쾰른
프리스조프 스제스니
젠스 온켄
구이도 루에싱
Original Assignee
애보트 프러덕츠 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37401623&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101302841(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 애보트 프러덕츠 게엠베하 filed Critical 애보트 프러덕츠 게엠베하
Publication of KR20080034516A publication Critical patent/KR20080034516A/ko
Application granted granted Critical
Publication of KR101302841B1 publication Critical patent/KR101302841B1/ko
Assigned to 애보트 래버러토리즈 게엠베하 reassignment 애보트 래버러토리즈 게엠베하 권리의 전부이전등록 Assignors: 애보트 프러덕츠 게엠베하
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Finger-Pressure Massage (AREA)
KR1020087006201A 2005-08-15 2006-08-15 장용코팅에 적합한 판크레아틴 미세펠릿 코어 Expired - Lifetime KR101302841B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US70852605P 2005-08-15 2005-08-15
EP05107474.8 2005-08-15
US60/708,526 2005-08-15
EP05107474 2005-08-15
PCT/EP2006/065313 WO2007020260A2 (en) 2005-08-15 2006-08-15 Pancreatin micropellet cores suitable for enteric coating

Publications (2)

Publication Number Publication Date
KR20080034516A KR20080034516A (ko) 2008-04-21
KR101302841B1 true KR101302841B1 (ko) 2013-09-02

Family

ID=37401623

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020087006201A Expired - Lifetime KR101302841B1 (ko) 2005-08-15 2006-08-15 장용코팅에 적합한 판크레아틴 미세펠릿 코어

Country Status (15)

Country Link
EP (1) EP1931317B1 (enExample)
JP (1) JP5284092B2 (enExample)
KR (1) KR101302841B1 (enExample)
AT (1) ATE418329T1 (enExample)
AU (1) AU2006281415B2 (enExample)
CA (1) CA2619477C (enExample)
DE (1) DE602006004471D1 (enExample)
ES (1) ES2320174T3 (enExample)
IL (1) IL189457A (enExample)
MX (1) MX2008001557A (enExample)
NO (1) NO20081379L (enExample)
PL (1) PL1931317T3 (enExample)
PT (1) PT1931317E (enExample)
RU (1) RU2408364C2 (enExample)
WO (1) WO2007020260A2 (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6632429B1 (en) 1999-12-17 2003-10-14 Joan M. Fallon Methods for treating pervasive development disorders
US20070053895A1 (en) 2000-08-14 2007-03-08 Fallon Joan M Method of treating and diagnosing parkinsons disease and related dysautonomic disorders
IT1319655B1 (it) 2000-11-15 2003-10-23 Eurand Int Microsfere di enzimi pancreatici con elevata stabilita' e relativometodo di preparazione.
US8030002B2 (en) 2000-11-16 2011-10-04 Curemark Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
CA2560613C (en) 2004-03-22 2015-11-24 Solvay Pharmaceuticals Gmbh Oral pharmaceutical compositions of lipase-containing products, in particular of pancreatin, containing surfactants
PL2278002T3 (pl) 2005-07-29 2017-12-29 Abbott Laboratories Gmbh Pankreatyna o zmniejszonej zawartości wirusowej
US11266607B2 (en) 2005-08-15 2022-03-08 AbbVie Pharmaceuticals GmbH Process for the manufacture and use of pancreatin micropellet cores
US9198871B2 (en) 2005-08-15 2015-12-01 Abbott Products Gmbh Delayed release pancreatin compositions
US20080058282A1 (en) 2005-08-30 2008-03-06 Fallon Joan M Use of lactulose in the treatment of autism
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US10072256B2 (en) 2006-05-22 2018-09-11 Abbott Products Gmbh Process for separating and determining the viral load in a pancreatin sample
PT2079445E (pt) 2007-02-20 2016-02-29 Allergan Pharmaceuticals Internat Ltd Composições de enzimas digestivas estáveis
BRPI0906439A2 (pt) * 2008-01-03 2018-12-04 Abbott Products Gmbh composições farmacêuticas que compreendem grânulos de lipase microbiana purificada e métodos para a prevenção ou tratamento de distúrbios digestivos
WO2009109856A2 (en) 2008-03-07 2009-09-11 Axcan Pharma Inc. Method for detecting infectious parvovirus in pharmaceutical preparations
US8658163B2 (en) 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
US8084025B2 (en) 2008-04-18 2011-12-27 Curemark Llc Method for the treatment of the symptoms of drug and alcohol addiction
US9320780B2 (en) 2008-06-26 2016-04-26 Curemark Llc Methods and compositions for the treatment of symptoms of Williams Syndrome
PL2318035T3 (pl) 2008-07-01 2019-10-31 Curemark Llc Sposoby i kompozycje do leczenia objawów zaburzeń neurologicznych i zaburzeń zdrowia psychicznego
US10776453B2 (en) 2008-08-04 2020-09-15 Galenagen, Llc Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain
US20100092447A1 (en) 2008-10-03 2010-04-15 Fallon Joan M Methods and compositions for the treatment of symptoms of prion diseases
CA2747703C (en) 2009-01-06 2021-06-15 Curemark Llc Compositions and methods for the treatment or the prevention of infections by e. coli
JP5684725B2 (ja) 2009-01-06 2015-03-18 キュレロン リミテッド ライアビリティ カンパニー 黄色ブドウ球菌感染の治療または予防のための組成物および方法ならびに表面上にいる黄色ブドウ球菌の根絶または低減のための組成物および方法
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
EP2440210A4 (en) 2009-06-12 2014-01-29 Meritage Pharma Inc METHOD FOR THE TREATMENT OF STOMACH DARM DISEASES
PL2295039T5 (pl) 2009-08-28 2023-02-27 Nordmark Pharma Gmbh Sposób wytwarzania granulek zawierających pankreatynę, w szczególności mikrogranulek zawierających pankreatynę, oraz wytworzone tym sposobem granulki zawierające pankreatynę
US9511125B2 (en) 2009-10-21 2016-12-06 Curemark Llc Methods and compositions for the treatment of influenza
EA029101B1 (ru) 2010-10-01 2018-02-28 Апталис Фарма Лимитид Составы с низкой дозой панкрелипазы и кишечнорастворимым покрытием
EP2489349B1 (de) 2011-02-17 2014-05-28 Nordmark Arzneimittel GmbH & Co.KG Pankreatin-Pellets, insbesondere Pankreatin-Mikropellets, und Verfahren zu deren Herstellung
DE202011000728U1 (de) 2011-03-30 2011-06-09 Nordmark Arzneimittel GmbH & Co. KG, 25436 Pankreatin-Pellets, insbesondere Pankreatin-Mikropellets
DK2701733T3 (da) 2011-04-21 2019-05-27 Curemark Llc Forbindelser til behandling af neuropsykiatriske forstyrrelser
CA2843556A1 (en) 2011-08-08 2013-02-14 Aptalis Pharma Ltd. Method for dissolution testing of solid compositions containing digestive enzymes
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
EP3639846B1 (en) 2013-08-09 2022-09-28 Allergan Pharmaceuticals International Limited Digestive enzyme composition suitable for enteral administration
EP3157568A1 (en) 2014-06-19 2017-04-26 Aptalis Pharma Limited Methods for removing viral contaminants from pancreatic extracts
CN114917328B (zh) 2014-11-05 2025-06-20 雅培制药股份有限公司 用于生产具有改善的安全特性的具有脂肪酶活性的组合物和适用于药物用途的组合物的方法
DE102017104482A1 (de) * 2017-03-03 2018-09-06 Nordmark Arzneimittel Gmbh & Co. Kg Pharmazeutische Zusammensetzung umfassend Pankreatin und einen lipasehaltigen Überzug
WO2018191233A1 (en) 2017-04-10 2018-10-18 Curemark, Llc Compositions for treating addiction
RU2706003C1 (ru) * 2019-09-09 2019-11-13 Акционерное общество "АВВА РУС" Микрогранулы, содержащие панкреатин
MX2022014395A (es) * 2020-06-10 2022-12-02 Kusum Healthcare Pvt Ltd Composicion farmaceutica de pancreatina.
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses
KR102950325B1 (ko) 2024-01-26 2026-04-08 황준영 판크레아틴 함유 속방성 장용코팅 정제

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004524838A (ja) * 2001-01-19 2004-08-19 ゾルファイ　ファーマスーティカルズ　ゲゼルシャフト　ミット　ベシュレンクテル　ハフツング 微生物酵素の新規混合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1509866A (en) * 1975-06-10 1978-05-04 Johnson & Johnson Enteric coated digestive enzyme compositions
DE4227385A1 (de) * 1992-08-19 1994-02-24 Kali Chemie Pharma Gmbh Pankreatinmikropellets
KR19990072826A (ko) * 1998-02-26 1999-09-27 우재영 판크레아틴장용코팅과립의제조방법
UA69413C2 (uk) * 1998-05-22 2004-09-15 Брістол-Майерс Сквібб Компані Фармацевтична композиція, яка містить серцевину та ентеросолюбільну оболонку, фармацевтична композиція у вигляді сфероїдальних гранул, спосіб одержання сфероїдальних гранул та спосіб одержання фармацевтичної композиції
BR0009012A (pt) * 1999-03-17 2001-12-26 Solvay Pharm Gmbh Medicamento para o tratamento de diabete
IT1319655B1 (it) * 2000-11-15 2003-10-23 Eurand Int Microsfere di enzimi pancreatici con elevata stabilita' e relativometodo di preparazione.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004524838A (ja) * 2001-01-19 2004-08-19 ゾルファイ　ファーマスーティカルズ　ゲゼルシャフト　ミット　ベシュレンクテル　ハフツング 微生物酵素の新規混合物

Also Published As

Publication number Publication date
WO2007020260A3 (en) 2007-05-10
AU2006281415A1 (en) 2007-02-22
DE602006004471D1 (de) 2009-02-05
RU2008109651A (ru) 2009-09-27
AU2006281415B2 (en) 2012-01-19
ES2320174T3 (es) 2009-05-19
PL1931317T3 (pl) 2009-06-30
IL189457A0 (en) 2008-06-05
EP1931317A2 (en) 2008-06-18
PT1931317E (pt) 2009-02-02
MX2008001557A (es) 2008-02-15
CA2619477A1 (en) 2007-02-22
KR20080034516A (ko) 2008-04-21
EP1931317B1 (en) 2008-12-24
JP2009504710A (ja) 2009-02-05
HK1119559A1 (en) 2009-03-13
RU2408364C2 (ru) 2011-01-10
JP5284092B2 (ja) 2013-09-11
IL189457A (en) 2014-05-28
WO2007020260A2 (en) 2007-02-22
ATE418329T1 (de) 2009-01-15
CA2619477C (en) 2015-05-26
NO20081379L (no) 2008-05-14

Similar Documents

Publication Publication Date Title
US20240148660A1 (en) Process for the manufacture and use of pancreatin micropellet cores
KR20080034516A (ko) 장용코팅에 적합한 판크레아틴 미세펠릿 코어
US9198871B2 (en) Delayed release pancreatin compositions
EP1931316B1 (en) Controlled release pharmaceutical compositions for acid labile drugs
JP2009504710A5 (enExample)
NZ565959A (en) Pancreatin micropellet cores suitable for enteric coating
KR101344546B1 (ko) 산 불안정성 약제를 위한 조절방출 약제학적 조성물
US20240226249A9 (en) Controlled release pharmaceutical compositions for acid-labile drugs
HK1119559B (en) Pancreatin micropellet cores suitable for enteric coating
HK1121037B (en) Controlled release pharmaceutical compositions for acid labile drugs

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20080313

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20110617

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20121220

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20130626

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20130827

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20130827

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20160629

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20160629

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20170629

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20170629

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20180628

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20180628

Start annual number: 6

End annual number: 6

FPAY Annual fee payment

Payment date: 20190624

Year of fee payment: 7

PR1001 Payment of annual fee

Payment date: 20190624

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20200624

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20220622

Start annual number: 10

End annual number: 10

PR1001 Payment of annual fee

Payment date: 20230626

Start annual number: 11

End annual number: 11

PR1001 Payment of annual fee

Payment date: 20240624

Start annual number: 12

End annual number: 12

PR1001 Payment of annual fee

Payment date: 20250625

Start annual number: 13

End annual number: 13